271 related articles for article (PubMed ID: 34030727)
1. Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo.
Sarkar S; Bardai F; Olsen AL; Lohr KM; Zhang YY; Feany MB
Mol Neurodegener; 2021 May; 16(1):33. PubMed ID: 34030727
[TBL] [Abstract][Full Text] [Related]
2. Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.
Bardai FH; Ordonez DG; Bailey RM; Hamm M; Lewis J; Feany MB
PLoS Biol; 2018 Dec; 16(12):e2006265. PubMed ID: 30571694
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
Henderson MX; Peng C; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
[TBL] [Abstract][Full Text] [Related]
4. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.
Liu J; Li T; Thomas JM; Pei Z; Jiang H; Engelender S; Ross CA; Smith WW
Hum Mol Genet; 2016 Feb; 25(4):672-80. PubMed ID: 26744328
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity.
Olsen AL; Feany MB
Neurobiol Dis; 2021 Nov; 159():105482. PubMed ID: 34390834
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein.
Brzozowski CF; Hijaz BA; Singh V; Gcwensa NZ; Kelly K; Boyden ES; West AB; Sarkar D; Volpicelli-Daley LA
Acta Neuropathol Commun; 2021 Nov; 9(1):180. PubMed ID: 34749824
[TBL] [Abstract][Full Text] [Related]
9. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
[TBL] [Abstract][Full Text] [Related]
10. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
[TBL] [Abstract][Full Text] [Related]
11. Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons.
Schapansky J; Khasnavis S; DeAndrade MP; Nardozzi JD; Falkson SR; Boyd JD; Sanderson JB; Bartels T; Melrose HL; LaVoie MJ
Neurobiol Dis; 2018 Mar; 111():26-35. PubMed ID: 29246723
[TBL] [Abstract][Full Text] [Related]
12. The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.
Cresto N; Gardier C; Gubinelli F; Gaillard MC; Liot G; West AB; Brouillet E
Eur J Neurosci; 2019 Feb; 49(3):339-363. PubMed ID: 30269383
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils.
Russo I; Kaganovich A; Ding J; Landeck N; Mamais A; Varanita T; Biosa A; Tessari I; Bubacco L; Greggio E; Cookson MR
Neurobiol Dis; 2019 Sep; 129():67-78. PubMed ID: 31102768
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
[TBL] [Abstract][Full Text] [Related]
15. Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.
Huang G; Bloodgood DW; Kang J; Shahapal A; Chen P; Kaganovsky K; Kim JI; Ding JB; Shen J
J Neurosci; 2022 Jun; 42(23):4755-4765. PubMed ID: 35534227
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E
Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
[TBL] [Abstract][Full Text] [Related]
18. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
Daher JP
Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
[TBL] [Abstract][Full Text] [Related]
19. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
20. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
